Drug intelligence / Profile preview

BI0201 ADC

Development stage: Preclinical
Lead developer: Protheragen
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BI0201 ADC is a preclinical-stage antibody-drug conjugate (ADC) being developed by Protheragen for the treatment of solid tumors. The agent is designed to dual-target Human Epidermal Growth Factor Receptor 2 (HER2) and Trophoblast Cell-Surface Antigen 2 (Trop-2), two antigens frequently overexpressed in various carcinomas. By targeting both HER2 and Trop-2, BI0201 ADC aims to deliver a cytotoxic payload directly to malignant cells, potentially enhancing therapeutic efficacy and overcoming resistance mechanisms associated with single-target therapies.

Other names: BI0201BI-0201BI 0201

Targets

TOP1 (DNA Topoisomerase I)TACSTD2 (Tumor-associated calcium signal transducer 2)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on BI0201 ADC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI0201 ADC.

Explore the full profile